| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gianmarco Salvetti, Daniele Saccenti, Andrea Stefano Moro, Jacopo Lamanna, Mattia Ferr. Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials. Brain sciences. vol 14. issue 8. 2024-08-29. PMID:39199520. |
comparison between single-dose and two-dose psilocybin administration in the treatment of major depression: a systematic review and meta-analysis of current clinical trials. |
2024-08-29 |
2024-09-01 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
depression is a serious psychiatric disorder with a high incidence of morbidity and mortality and psilocybin with psychotherapy has emerged as a promising potential in the treatment of depressive disorders. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
a review of psilocybin use in patients with depressive disorders is presented.a search was conducted investigating the use of psilocybin in patients with depressive disorders and treatment resistant depression via pubmed/medline, embase, and google scholar in october 2023; all publication types were permitted and limited for english-language. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
keyword search terms included: "psilocybin" or "psychedelics" and "depression", or "major depressive disorder", or "treatment-resistant depression". |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
controlled and uncontrolled clinical trials utilizing psilocybin with psychological support for major depressive disorder and treatment-resistant depression, as well as in patients with depression and cancer related anxiety have demonstrated immediate and sustained antidepressant and anxiolytic effects. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
psilocybin may offer a valuable contribution as an option to the currently available pharmacological and psychotherapeutic agents for patients with major depressive disorders, treatment-resistant depression as well as for patients with depression and comorbid terminal cancer. |
2024-08-23 |
2024-08-25 |
Not clear |
| Baeleigh VanderZwaag, Albert Garcia-Romeu, Mauricio A Garcia-Barrer. Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery. Therapeutic advances in psychopharmacology. vol 14. 2024-08-12. PMID:39132012. |
psilocybin is one of the most widely studied classic psychedelics which has shown good safety and clinical benefit for major depression and substance use disorders. |
2024-08-12 |
2024-08-14 |
Not clear |
| André Do, Vanessa Michaud, Jean-François Stephan, Miltiadis Moreau, Élise Benoît, Félix-Antoine Bérubé, Antoine Bibaud-De Serres, Alain Taillefer, Philippe Vincen. Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. Frontiers in psychiatry. vol 15. 2024-08-01. PMID:39086732. |
psilocybin has reemerged as a promising treatment for difficult-to-treat depression (dtd). |
2024-08-01 |
2024-08-03 |
Not clear |
| Amanda Paige Hanstein, Chance Felchli. Treating Anxiety and Depression With Psilocybin Therapy. Radiologic technology. vol 95. issue 6. 2024-07-30. PMID:39079732. |
treating anxiety and depression with psilocybin therapy. |
2024-07-30 |
2024-08-02 |
Not clear |
| Husam Bader, Husam Farraj, Joud Maghnam, Yazan Abu Oma. Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis. World journal of clinical oncology. vol 15. issue 7. 2024-07-29. PMID:39071471. |
psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms, is known for its effects on anxiety and depression. |
2024-07-29 |
2024-08-02 |
Not clear |
| Siyi Zheng, Rong Ma, Yang Yang, Gang L. Psilocybin for the treatment of Alzheimer's disease. Frontiers in neuroscience. vol 18. 2024-07-26. PMID:39050672. |
psilocybin, a psychoactive alkaloid intrinsic to hallucinogenic mushrooms, has garnered attention within the neuropsychiatric realm due to its established safety and efficacy in treating depression. |
2024-07-26 |
2024-07-28 |
Not clear |
| Mariana Zarankin, María S Pellegrini, Francisco Zenten. Psilocybin fungi microdose treatment in major depressive disorder: a case report Vertex (Buenos Aires, Argentina). vol 35. issue 164, abr.-jun.. 2024-07-18. PMID:39024488. |
psilocybin fungi microdose treatment in major depressive disorder: a case report major depression disorder is an entity with high prevalence and worldwide impact. |
2024-07-18 |
2024-09-08 |
Not clear |
| Mariana Zarankin, María S Pellegrini, Francisco Zenten. Psilocybin fungi microdose treatment in major depressive disorder: a case report Vertex (Buenos Aires, Argentina). vol 35. issue 164, abr.-jun.. 2024-07-18. PMID:39024488. |
accompanimentand patient advice was made appealing to the right of autonomy, on the psilocybin microdose self-administration process, aiming to reducing health risks and potentiate probable beneficial effects, with weekly evaluations, for a period of 7 months; using clinical anamnesis, laboratory tests and the hamilton depression scale. |
2024-07-18 |
2024-09-08 |
Not clear |
| Mariana Zarankin, María S Pellegrini, Francisco Zenten. Psilocybin fungi microdose treatment in major depressive disorder: a case report Vertex (Buenos Aires, Argentina). vol 35. issue 164, abr.-jun.. 2024-07-18. PMID:39024488. |
these findings support the idea that psilocybin microdose treatments are promising tools in depression treatments. |
2024-07-18 |
2024-09-08 |
Not clear |
| Kolasa Magdalena, Nikiforuk Agnieszka, Korlatowicz Agata, Solich Joanna, Potasiewicz Agnieszka, Marta Dziedzicka-Wasylewska, Bugno Ryszard, Hogendorf Adam, Bojarski Andrzej, Faron-Górecka Agat. Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. Psychopharmacology. 2024-07-04. PMID:38963553. |
our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of psilocybin (psi) in treating treatment-resistant depression (trd). |
2024-07-04 |
2024-07-10 |
rat |
| Joshua M Poulin, Gregory E Bigford, Krista L Lanctôt, Peter Giacobbe, Ayal Schaffer, Mark Sinyor, Jennifer S Rabin, Mario Masellis, Amit Singnurkar, Christopher B Pople, Nir Lipsman, Muhammad I Husain, Joshua D Rosenblat, Xingshan Cao, Bradley J MacIntosh, Sean M Nesto. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression. Trials. vol 25. issue 1. 2024-07-03. PMID:38956594. |
engaging mood brain circuits with psilocybin (embrace): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression. |
2024-07-03 |
2024-07-06 |
Not clear |
| Joshua M Poulin, Gregory E Bigford, Krista L Lanctôt, Peter Giacobbe, Ayal Schaffer, Mark Sinyor, Jennifer S Rabin, Mario Masellis, Amit Singnurkar, Christopher B Pople, Nir Lipsman, Muhammad I Husain, Joshua D Rosenblat, Xingshan Cao, Bradley J MacIntosh, Sean M Nesto. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression. Trials. vol 25. issue 1. 2024-07-03. PMID:38956594. |
we aim to examine for the first time how psilocybin acutely (intraday) and subacutely (weeks) alters functional brain networks implicated in depression. |
2024-07-03 |
2024-07-06 |
Not clear |
| Daisuke Ib. [Up-to-Date on clinical and preclinical studies of psilocybin therapy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. vol 159. issue 4. 2024-06-30. PMID:38945903. |
in 2016, carhart-harris and colleagues reported that psilocybin, the hallucinogenic compound derived from magic mushrooms, exhibits rapid and enduring antidepressant effects in patients with treatment-resistant depression. |
2024-06-30 |
2024-07-03 |
Not clear |
| Daisuke Ib. [Up-to-Date on clinical and preclinical studies of psilocybin therapy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. vol 159. issue 4. 2024-06-30. PMID:38945903. |
in 2018 and 2019, the u.s. food and drug administration designated psilocybin as a "breakthrough medicine" for treatment-resistant depression and mdd, respectively. |
2024-06-30 |
2024-07-03 |
Not clear |
| David S Jacobs, Alina P Bogachuk, Chloé L Le Moing, Bita Moghadda. Effects of psilocybin on uncertain punishment learning. Neurobiology of learning and memory. 2024-06-23. PMID:38909970. |
psilocybin may provide a useful treatment for mood disorders including anxiety and depression but its mechanisms of action for these effects are not well understood. |
2024-06-23 |
2024-06-26 |
rat |